Stay updated on Grapiprant and Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The page's Locations section was updated to include entries for California, Michigan, Pennsylvania, and Virginia, and the revision tag updated to v3.3.3; the HHS Vulnerability Disclosure link was removed.
    Difference
    0.6%
    Check dated 2025-12-22T21:45:42.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    23 days ago
    No Change Detected
  5. Check
    30 days ago
    Change Detected
    Summary
    The page shows a revision update to v3.3.2, replacing the previous v3.3.1. No substantive study details, eligibility criteria, endpoints, or enrollment changes are observed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-01T11:48:36.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    Revision history updated from v3.2.0 to v3.3.1; no changes to study details or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T10:55:35.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Summary
    The government funding lapse notice was removed from the page, which previously warned that information may not be up to date due to funding gaps. This is an administrative change that does not affect trial data or core content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-17T06:08:38.000Z thumbnail image
  8. Check
    58 days ago
    Change Detected
    Summary
    No substantive changes to the Study Details page were detected; all key sections and information remain as in the previous view.
    Difference
    0.5%
    Check dated 2025-11-03T00:44:59.000Z thumbnail image
  9. Check
    87 days ago
    Change Detected
    Summary
    Updated version to v3.2.0 and added a government-operating-status notice; removed the prior v3.1.0 tag.
    Difference
    4%
    Check dated 2025-10-05T07:23:09.000Z thumbnail image

Stay in the know with updates to Grapiprant and Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.